Clinical Trial Update: Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders [Phase 1]

View source ↗

Summary

Phase 1 trial update for Epcoritamab in relapsed or refractory post-transplant lymphoproliferative disorders, including DLBCL-type PTLD and EBV-related PTLD, cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Ebv-related Post-transplant Lymphoproliferative Disorder
• Monomorphic Post-transplant Lymphoproliferative Disorder
• Polymorphic Post-transplant Lymphoproliferative Disorder
• Post-transplant Lymphoproliferative Disorder

Drugs mentioned

• Epcoritamab (epcoritamab)

Snippet

Sponsor: Timothy Voorhees | Conditions: Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder, EBV-Related Post-Transplant Lymphoproliferative Disorder | Phase 1 | Status: RECRUITING